If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
By failing to close on the enemy earlier and more forcefully, his critics argue, he squandered an opportunity to destroy the entire Japanese Mobile Fleet. "This is what comes of placing a non-aviator in command over carriers" was the common refrain. Admiral John Towers, a naval aviation pioneer and Deputy Commander-in-Chief Pacific Fleet, demanded that Spruance be relieved. The request was denied by Nimitz. Moreover, Spruance was supported in his decision by Admiral Kelly Turner and Admiral Ernest King, Chief of Naval Operations. Spruance's caution (in particular, his suspicion of a diversionary force) can be compared with Admiral William Halsey's headlong pursuit of an actual diversionary force at Leyte Gulf four months later. Halsey left the American invasion fleet weakly protected during the Battle off Samar, nearly resulting in a devastating attack on the landing force by Japanese heavy surface units. It was prevented only by the heroic and desperate attack of 5 small American surface ships, which put up such an intense fight that the 23-ship-strong Japanese fleet thought they were engaging a much larger force and withdrew. In addition, by focusing on defense first, the carrier forces under Spruance at Philippine Sea suffered no significant harm. This was in contrast to Leyte Gulf when Halsey's carriers were trying to neutralize the enemy airfields and attack the enemy fleet simultaneously, such that a Japanese bomber managed to evade the Combat Air Patrols to fatally cripple the light carrier USS Princeton. Likewise, during the carrier-based air raids, U.S.
== Interfacial potential == An interface is defined as the common boundary formed between two different phases, such as between a solid and gas. Electric potential, or charge, is the result of an object's capacity to be moved in an electric field. An interfacial potential is thus defined as a charge located at the common boundary between two phases (for example, an amino acid such as glutamate on the surface of a protein can have its side chain carboxylic acid deprotonated in environments with pH greater than 4.1 to produce a charged amino acid at the surface, which would create an interfacial potential). Interfacial potential is responsible for the formation of the electric double layer, which has a broad range of applications in what is termed electrokinetic phenomena. The development of the theory of the electric double layer is described below.
There were 5,834 households, out of which 32.7% had children under the age of 18 living with them, 50.5% were married couples living together, 10.9% had a female householder with no husband present, and 35.2% were non-families. 29.9% of all households were made up of individuals, and 11.8% had someone living alone who was 65 years of age or older. The average household size was 2.40 and the average family size was 2.99. In the city, the population was spread out, with 26.7% under the age of 18, 9.0% from 18 to 24, 30.8% from 25 to 44, 19.9% from 45 to 64, and 13.7% who were 65 years of age or older. The median age was 34 years. For every 100 females, there were 91.2 males. For every 100 females age 18 and over, there were 85.8 males. The median income for a household in the city was $37,791, and the median income for a family was $47,769. Males had a median income of $35,614 versus $22,791 for females. The per capita income for the city was $18,245. About 4.4% of families and 7.1% of the population were below the poverty line, including 6.4% of those under age 18 and 10.6% of those age 65 or over.
== Structure == The lamina propria is a loose connective tissue, hence it is not as fibrous as the underlying connective tissue of the submucosa. The connective tissue and architecture of the lamina propria is very compressible and elastic, this can be seen in organs that require expansion such as the bladder. The collagen in the lamina propria of elastic organs has been shown to play a major role in mechanical function. In the bladder the collagen composition of its lamina propria allows for structure, tensile strength, and compliance, through complex coiling. It has been suggested that myofibroblasts also reside in the lamina propria of several organs. These cells have characteristics of both smooth muscle and fibroblasts. The lamina propria may also be rich in vascular networks, lymphatic vessels, elastic fibers, and smooth muscle fascicles from the muscularis mucosae. Afferent and efferent nerve endings can be found in the lamina propria as well. Immune cells as well as lymphoid tissue, including lymphoid nodules and capillaries, may be present. Smooth muscle fibers may be in the lamina propria, such as in the intestinal villi. It is practically void of fat cells. Lymphatics penetrate the mucosa and lie below the basement membrane of the epithelium, from there they drain the lamina propria. The fast rate of cell death and regeneration of the epithelium leaves behind many apoptotic cell bodies. These have been found to go into the lamina propria, most of which are inside its macrophages.
Journal of Clinical Investigation (Papers Presented / Proceedings of the Fifty-Fourth Annual Meeting of the American Society for Clinical Investigation, April 30, 1962. 41 (6): 1340. Daly, M.M.; Deming, Q.B.; Raeff, V.M.; Brun, L.M. (October 1963). "Cholesterol Concentration and Cholesterol Synthesis in Aortas of Rats With Renal Hypertension" (PDF). Journal of Clinical Investigation. 42 (10): 1606–1612. doi:10.1172/JCI104845. PMC 289439. PMID 14074354. Adel, H.N.; Deming, Q.B.; Daly, M.M.; Raeff, V.M.; Brun, L.M. (October 1965). "The Effect of Experimental Hypertension on Cholesterol Synthesis in the Rat". Journal of Clinical and Laboratory Medicine. 66 (4): 571–581. PMID 5843085. Wolinsky, Harvey; Daly, Marie M. (November 1970). "A Method for the Isolation of Intima-Media Samples from Arteries". Proceedings of the Society for Experimental Biology and Medicine. 135 (2): 364–368. doi:10.3181/00379727-135-35052. PMID 4921030. S2CID 46610507. Daly, M.M. (May 1971). "Biosynthesis of squalene and sterols by rat aorta". Journal of Lipid Research. 12 (3): 367–375. doi:10.1016/S0022-2275(20)39518-3. PMID 5579265. Daly, Marie M. (September 1972). "Effects of Hypertension on the Lipid Composition of Rat Aortic Intima-Media". Circulation Research. 31 (3): 410–416. doi:10.1161/01.res.31.3.410. PMID 5057020. S2CID 12008214. Wolinsky, Harvey; Goldfischer, Sidney; Daly, Marie M.; Kasak, Lisa E.; Coltoff-Schiller, Bernice (April 1975). "Arterial Lysosomes and Connective Tissue in Primate Atherosclerosis and Hypertension". Circulation Research. 36 (4): 553–561. doi:10.1161/01.res.36.4.553.
Sources: en.wikipedia.org
At rates of use at that time (72 million SCM per year in the U.S.; see pie chart below) this would have been enough helium for about 58 years of U.S. use, and less than this (perhaps 80% of the time) at world use rates, although factors in saving and processing impact effective reserve numbers. Helium is commercially available in either liquid or gaseous form. As a liquid, it can be supplied in small insulated containers called dewars which hold as much as one cubic metre (1,000 L) of helium, or in large ISO containers, which have nominal capacities as large as 42 m3 (around 11,000 U.S. gallons). In gaseous form, small quantities of helium are supplied in high-pressure cylinders holding as much as 8 m3 (approximately .282 standard cubic feet), while large quantities of high-pressure gas are supplied in tube trailers, which have capacities of as much as 4,860 m3 (approx. 172,000 standard cubic feet).
== Treatment == SJS constitutes a dermatological emergency. Patients with documented Mycoplasma infections can be treated with oral macrolide or oral doxycycline. Initially, treatment is similar to that for patients with thermal burns, and continued care can only be supportive (e.g., intravenous fluids and nasogastric or parenteral feeding) and symptomatic (e.g., analgesic mouth rinse for mouth ulcer). Dermatologists and surgeons tend to disagree about whether the skin should be debrided. Beyond this kind of supportive care, no treatment for SJS is accepted. Treatment with corticosteroids is controversial. Early retrospective studies suggested corticosteroids increased hospital stays and complication rates. No randomized trials of corticosteroids have been conducted for SJS, and it can be managed successfully without them. Other agents have been used, including cyclophosphamide and ciclosporin, but none have exhibited much therapeutic success. Intravenous immunoglobulin treatment has shown some promise in reducing the length of the reaction and improving symptoms. Other common supportive measures include the use of topical pain anesthetics and antiseptics, maintaining a warm environment, and intravenous analgesics. An ophthalmologist should be consulted immediately, as SJS frequently causes the formation of scar tissue inside the eyelids, leading to corneal vascularization, impaired vision, and a host of other ocular problems.
Synthesis: The chemical must be produced within the neuron or be present in it as a precursor molecule. Release and response: When the neuron is activated, the chemical must be released and elicit a response in target cells or neurons. Experimental response: Application of the chemical directly to the target cells should produce the same response observed when the chemical is naturally released from neurons. Removal mechanism: There must be a mechanism in place to remove the neurotransmitter from its site of action once its signaling role is complete. However, given advances in pharmacology, genetics, and chemical neuroanatomy, the term "neurotransmitter" can be applied to chemicals that:
== Early life and education == Santosh Shivaji Lad was born on 27 February 1975 in Sandur in present-day Ballari district, Karnataka. His father was Shivaji V. Lad. Lad completed a Bachelor of Commerce degree from SESS College, Sandur, in 1997, according to his election affidavit. Lad's family has been associated with business interests in Sandur and the Ballari region. His professional occupation was listed as business/entrepreneur in his 2023 election affidavit. Santosh Lad, son of Shailaja and Lt. Shivaji Lad, was born on 27 February 1975 in Sandur taluk of Karnataka's Bellary district. He has one elder sister. His family was affluent because of their involvement in the mining industry since the 1950s. Lad was an active sportsman as a youngster and participated in local tournaments and state-level competitions. He participated in under-21 Cricket state-level tournament KSCA representing Tumkur Zone as a team member and as captain.
Arguing in favour of independence, President Mangope claimed that the move would enable its population to negotiate with Pretoria from a stronger position: "We would rather face the difficulties of administering a fragmented territory, the wrath of the outside world, and accusations of ill-informed people. It's the price we are prepared to pay for being masters of our own destiny." United Nations Secretary-General Kurt Waldheim stated that he "strongly deplored" the establishment of "another so-called independent tribal homeland in pursuance of the discredited policies of apartheid", and in resolution A/RES/32/105N, passed on 14 December 1977, the United Nations General Assembly linked Bophuthatswana's "so-called 'independence'" to South Africa's "stubborn pursuit" of its policies, and called upon all governments to "deny any form of recognition to the so-called 'independent' bantustans". During a parliamentary debate in the UK on 6 December 1977, Foreign Secretary David Owen replied in the negative when asked "whether Her Majesty's Government intend to recognise travel documents issued by the authorities of ... Bophuthatswana for the purpose of admitting visitors to the United Kingdom". While the majority of news reports echoed these official declarations, there were others which opined that Western critics should "suspend judgment for a time", and despite its generally critical stance on South Africa's policies, Time magazine wrote that Bophuthatswana had "considerable economic potential" with an expected $30 million a year coming from mining revenues.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.